Building or investing in the in vivo CAR-T market? Get our report

In vivo CAR-T is one of the hottest corners of biotech in 2026, even though nearly every program is still in early trials or in the lab.

We've found a lot of interesting signals. For example, Bristol Myers Squibb agreed to buy Orbital Therapeutics for $1.5B in October 2025, for an RNA-based program that hadn't yet reached patients. And in July 2026, J&J committed $785M upfront to Sail Biomedicines, with an option to buy it for $2.58B. Big drugmakers are paying early for a chance to make CAR-T without a factory, starting with autoimmune diseases.

In this section, we look at why pharma is buying so early, why many programs start with autoimmune diseases rather than cancer, and what these prices mean for the startups that are still independent.

Classic CAR-T can work wonders in some blood cancers, but it takes weeks to make, needs chemotherapy first, and reaches only a small share of the patients who could use it.

We look at six types of companies, from viral vector and lipid nanoparticle developers to gene editing and DNA delivery platforms. Their buyers and partners are mostly big pharma, along with cancer and autoimmune specialists. For each, we rank the biggest pains, like reaching T cells without hitting the liver, controlling how strong the response gets, and staying safe when the therapy can't be pulled back.

This shows which problems partners will pay to solve now, and which still need human data first.

No in vivo CAR-T company sells a product yet. They make money through pharma partnerships, upfront payments, milestones and, more and more often, the sale of the whole company.

We compare these paths and show who pays, and when. A platform deal brings cash early but hands the best programs to a partner. Keeping a program in-house keeps the upside, but trials in cancer and autoimmune disease are expensive. And once products launch, their price will be compared with classic CAR-T, which needs a custom factory run for each patient.

You'll see which models bring in cash before the first approval, and which only pay off if the science works in patients.

Behind our growth estimate are a few forces that must keep working. This section walks through each one.

Some drivers are clear: no cell collection, no factory per patient, and a possible use in common autoimmune diseases like lupus. Others feed each other. Each human result makes the next partnership easier to sign. Pharma money pays for better delivery. And better delivery could make treatment simple enough for regular hospitals, not just top cancer centers.

Before building or investing, you should know what it takes for an off-the-shelf infusion to work safely in many patients, at a price that lets them get it.

Capstan Therapeutics and EsoBiotec became the field's reference names when AbbVie and AstraZeneca bought them, but many more teams are racing behind them.

Several smaller companies work on one piece of the problem. Some design particles that only bind to T cells. Others build vectors that insert the gene in a safe spot, or add switches that let doctors turn the cells off. A growing number are in China, where early human studies can start quickly.

They're hard to compare because they use different delivery tools, target different diseases and report results from a handful of patients. Many also work inside pharma partnerships, so their best data stays private.

Below, you'll find the market grids and ecosystem maps we've built to show who uses which delivery method, for which disease, and where new players are getting in.

Umoja Biopharma, CREATE Medicines, MagicRNA… a few in vivo CAR-T teams have already reached human trials. None has proven its approach yet.

Umoja Biopharma uses a lentiviral vector to make CAR-T cells inside the body and is testing it in blood cancers. CREATE Medicines delivers RNA in lipid nanoparticles and says it has dosed more than 50 patients across its programs. MagicRNA, based in Shenzhen, published early results in lupus in The New England Journal of Medicine. The data are promising but still small.

We'll look at how these teams moved from animals to patients, picked a first disease, and raised money without selling too early.